GEN Exclusives

More »

GEN News Highlights

More »
Jun 25, 2008

Osiris Obtains $2M from JDRF with Clinical Advancement of Stem Cell Therapy

  • Osiris Therapeutics received $2 million from the Juvenile Diabetes Research Foundation (JDRF) for progressing its mesenchymal stem cell (MSC) therapy into a Phase II study. The milestone payments were triggered by Osiris accomplishing certain clinical and regulatory goals including initiating patient treatments.

    Prochymal is being tested in patients recently diagnosed with type 1 diabetes. “Our ultimate goal with this research is to develop a treatment that we could give a patient at the onset to safely halt progression of the disease and preserve enough islet-cell function to avoid the need for insulin administration all together,” explains Jay S. Skyler, M.D., a study investigator and professor of medicine and associate director of the Diabetes Research Institute at the University of Miami.

    Prochymal is also currently in Phase III trials for graft vs. host disease and Crohn’s disease. “Because Prochymal has been shown to home to sites of inflammation and inhibit immune system attack in other disease states, we are very excited about evaluating its potential to alter the course of this debilitating condition,” remarks Kashif Latif, M.D., another study investigator for Osiris and medical director of the AM Diabetes and Endocrinology Center.

    The Phase II trial is evaluating Prochymal in preserving insulin production in patients 18 to 30 years. It is designed as a double-blind, placebo-controlled, multicenter trial with a target enrollment of 60 patients, according to Osiris. The primary endpoint of the trial will be the measurement of C-peptide produced after glucose stimulation.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?